Stock Scorecard
Stock Summary for United Therapeutics Corp (UTHR) - $503.86 as of 9/11/2026 9:54:59 AM EST
Total Score
12 out of 30
Safety Score
50 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for UTHR
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for UTHR
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for UTHR
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for UTHR
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for UTHR (50 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 10 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 6 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for UTHR
Financial Details for UTHR
Company Overview |
|
|---|---|
| Ticker | UTHR |
| Company Name | United Therapeutics Corp |
| Country | N/A |
| Description | United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland. |
| Sector Name | HEALTHCARE |
| Industry Name | DRUG MANUFACTURERS - SPECIALTY & GENERIC |
| Most Recent Quarter | 6/30/2026 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 503.86 |
| Price 4 Years Ago | 278.09 |
| Last Day Price Updated | 9/11/2026 9:54:59 AM EST |
| Last Day Volume | 653,159 |
| Average Daily Volume | 539,952 |
| 52-Week High | 609.35 |
| 52-Week Low | 388.73 |
| Last Price to 52 Week Low | 29.62% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 43.34 |
| Sector PE | 63.03 |
| 5-Year Average PE | 20.24 |
| Free Cash Flow Ratio | 11.99 |
| Industry Free Cash Flow Ratio | 18.44 |
| Sector Free Cash Flow Ratio | 24.32 |
| Current Ratio Most Recent Quarter | 5.73 |
| Total Cash Per Share | 42.04 |
| Book Value Per Share Most Recent Quarter | 149.97 |
| Price to Book Ratio | 3.44 |
| Industry Price to Book Ratio | 32.23 |
| Sector Price to Book Ratio | 12.03 |
| Price to Sales Ratio Twelve Trailing Months | 6.67 |
| Industry Price to Sales Ratio Twelve Trailing Months | 3.22 |
| Sector Price to Sales Ratio Twelve Trailing Months | 37.91 |
| Analyst Buy Ratings | 9 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 42,890,700 |
| Market Capitalization | 21,610,908,102 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 6.35% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 13.40% |
| Annual Earnings Growth | 11.68% |
| Reported EPS 12 Trailing Months | 27.90 |
| Reported EPS Past Year | 13.09 |
| Reported EPS Prior Year | 27.90 |
| Net Income Twelve Trailing Months | 1,310,900,000 |
| Net Income Past Year | 1,334,700,000 |
| Net Income Prior Year | 1,195,100,000 |
| Quarterly Revenue Growth YOY | -1.90% |
| 5-Year Revenue Growth | 16.50% |
| Operating Margin Twelve Trailing Months | 42.20% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 1,803,200,000 |
| Total Cash Past Year | 1,557,100,000 |
| Total Cash Prior Year | 1,697,200,000 |
| Net Cash Position Most Recent Quarter | 1,403,200,000 |
| Net Cash Position Past Year | 857,100,000 |
| Long Term Debt Past Year | 700,000,000 |
| Long Term Debt Prior Year | 300,000,000 |
| Total Debt Most Recent Quarter | 400,000,000 |
| Equity to Debt Ratio Past Year | 0.91 |
| Equity to Debt Ratio Most Recent Quarter | 0.94 |
| Total Stockholder Equity Past Year | 7,096,200,000 |
| Total Stockholder Equity Prior Year | 6,444,000,000 |
| Total Stockholder Equity Most Recent Quarter | 6,400,300,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 1,093,000,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 25.48 |
| Free Cash Flow Past Year | 1,040,700,000 |
| Free Cash Flow Prior Year | 1,080,600,000 |
Options |
|
| Put/Call Ratio | 0.03 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -4.37 |
| MACD Signal | -5.26 |
| 20-Day Bollinger Lower Band | 502.95 |
| 20-Day Bollinger Middle Band | 546.21 |
| 20-Day Bollinger Upper Band | 589.47 |
| Beta | 0.56 |
| RSI | 45.47 |
| 50-Day SMA | 506.34 |
| 150-Day SMA | 367.94 |
| 200-Day SMA | 335.90 |
System |
|
| Modified | 9/11/2026 3:30:15 AM EST |